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Abstract  
Objective:  
Single physical comorbidities have been associated with the premature mortality in people with 
schizophrenia-spectrum disorders (SSD). We investigated the association of physical multimorbidity 
(≥two physical health conditions) with mortality in people with SSD.  
Methods:  
A retrospective cohort study between 2013 and 2017. All people with a diagnosis of SSD (ICD-10: 
F20-F29), who had contact with secondary mental healthcare within South London during 2011-2012 
were included. A novel semantic search system captured conditions from electronic mental health 
records, and all-cause mortality were retrieved. Hazard ratios (HRs) and population attributable 
fractions (PAFs) were calculated for associations between physical multimorbidity and all-cause 
mortality. 
Results:  
Among the 9775 people with SSD (mean (SD) age, 45.9 (15.4); males, 59.3%), 6262 (64%) had 
physical multimorbidity, and 880 (9%) died during the 5-year follow-up. The top three physical 
multimorbidity combinations with highest mortality were cardiovascular-respiratory (HR: 2.23; 95% 
CI, 1.49-3.32), respiratory-skin (HR: 2.06; 95% CI, 1.31-3.24), and respiratory-digestive (HR: 1.88; 95% 
CI, 1.14-3.11), when adjusted for age, gender, and all other physical disease systems. Combinations 
of physical diseases with highest PAFs were cardiovascular-respiratory (PAF: 35.7%), neurologic-
respiratory (PAF: 32.7%), as well as respiratory-skin (PAF: 29.8%). 
Conclusions:  
Approximately 2/3 of patients with SSD had physical multimorbidity and the risk of mortality in these 
patients was further increased compared to those with none or single physical conditions. These 
findings suggest that in order to reduce the physical health burden and subsequent mortality in 
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people with SSD, proactive coordinated prevention and management efforts are required and 
should extend beyond the current focus on single physical comorbidities.  
Keywords: Schizophrenia, severe mental illness, mortality, somatic, comorbidity  
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1. Introduction  
People with schizophrenia have life expectancies up to 20 years shorter than those in the general 
population (Chang et al., 2011; Walker, McGee, & Druss, 2015). The majority of early deaths (70%) 
are explained by physical health conditions, such as cardiovascular, respiratory and neoplastic 
diseases (Correll, Solmi, et al., 2017; Jayatilleke et al., 2017). Despite the established worse physical 
health morbidity in people with schizophrenia (Oud & Meyboom-de Jong, 2009; Razzano et al., 
2015), most research to date has focused on single physical health conditions such as cardiovascular, 
respiratory disease, and diabetes (Schoepf et al., 2012; Vancampfort et al., 2016). However, in 
populations with poor physical health outcomes such as schizophrenia (DE Hert et al., 2011; Smith, 
Langan, McLean, Guthrie, & Mercer, 2013), people are often affected by two or more physical health 
conditions, termed physical health multimorbidity (Stubbs et al., 2016).  
In the general population, the number of people with physical multimorbidity has increased in most 
countries around the world and is becoming one of the main challenges for health care systems 
(Dhalwani et al., 2016). A large-scale systematic review of more than 70 million people from the 
general population across 12 different countries suggested that the prevalence of multimorbidity 
was 13% in people aged 18 years and older, and a positive association between age and prevalence 
of multimorbidity (Violan et al., 2014). Multimorbidity is a concern, with data from the general 
population demonstrating that people affected are more likely to have functional decline (A. Ryan, 
Wallace, O’Hara, & Smith, 2015), worse quality of life (Fortin et al., 2004), increased risk of 
premature mortality (Di Angelantonio et al., 2015) and higher healthcare costs (Lehnert et al., 2011).  
Whilst there have been concerted efforts to understand poor physical health in schizophrenia, little 
is known about the impact of physical health multimorbidity on mortality in these patients. 
However, recent evidence indicates a higher risk of physical health multimorbidity compared to the 
general population (Gabilondo, Alonso-Moran, Nuño-Solinis, Orueta, & Iruin, 2017; Stubbs et al., 
2016), and a recent large multinational study in low- and middle-income countries, concluded that 
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psychosis was associated with an increased odds ratio of 4.1 for physical multimorbidity, compared 
to controls (Stubbs et al., 2016). Stubbs et al. reported that psychosis patients had high levels of 
asthma combined with diabetes, angina pectoris or tuberculosis, and arthritis combined with angina 
pectoris, and hearing problems combined with visual impairment or edentulism (Stubbs et al., 2016). 
The study by Gabilondo et al. showed that physical disease clusters of neuropsychiatric conditions 
(Parkinson, dyspepsia, cerebrovascular disease) as well as cardiovascular and respiratory disease 
clusters were most common (Gabilondo et al., 2017). Even though such combinations show that 
physical morbidities co-occur frequently in patients with SSD, no studies have to date investigated 
the impact of such combinations to mortality, which is necessary in order to understand and possibly 
reduce the premature mortality in patients with SSD.  
Clearly, an improved evidence base is important to identify at risk groups, develop interventions, 
and address the premature mortality. Since SSD is a heterogeneous condition (Os & Kapur, 2009), 
which is associated with premature mortality (Walker et al., 2015) and greatly increased single 
physical health comorbidities, we aimed to investigate the prevalence of physical health 
multimorbidity in people with SSD. Secondly, we assessed which physical health conditions and 
clusters (i.e. combinations of physical disease systems) are likely to be associated with increased 
mortality rates in patients with SSD using data from a large electronic health record (EHR) platform.  
2. Methods  
2.1 Study design 
A retrospective cohort study using data from electronic mental health records linked to national 
mortality surveillance with a five-year follow-up period.  
2.2 Study period 
Cohort selection and characterisation used data from 2011-2012. Follow-up ran from January 1, 
2013 to December 31, 2017.  
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2.3 Data source 
Data were derived from the Clinical Record Interactive Search (CRIS); a case register system that 
contains de-identified electronic health record (EHR) data from the South London and Maudsley 
(SLaM) National Health Service Foundation Trust. SLaM is one of the largest mental healthcare 
services in Europe, providing comprehensive mental health care to a catchment of approximately 1.3 
million residents in south London (Croydon, Lambeth, Lewisham, and Southwark). EHRs have been 
used across all SLaM services since 2006, and CRIS was established with funding from the National 
Institute of Health Research (NIHR) as a ‘live’ resource, commencing with imported legacy data in 
2008 and accumulating information on the full SLaM caseload since that time (Perera et al., 2016). 
CRIS data are accessed and used within a robust governance model, and CRIS has received research 
ethics approval as a data resource for secondary analysis (Oxford REC C, reference 18/SC/0372).  
2.4 Study population  
The cohort included all individuals aged 18 years or older with a diagnosis of SSD (ICD-10: F20-F29) 
and had at least one face to face contact with SLaM during the period between 1st January 2011 and 
31st December 2012, and who were alive on 1st January 2013  (set up in this way to allow all cases to 
have at least 5 year follow-up). In recognition of the heterogeneous nature of schizophrenia, we 
included the spectrum of schizophrenia (SSD) as in accordance with previous research papers (Chang 
et al., 2010; Stubbs, Mueller, et al., 2018). We used primary and secondary diagnoses of F20-29 
within the structured ICD-10 codes that were recorded routinely in the source EHR. Physical health 
conditions were ascertained, using natural language processing (NLP) as described below, from data 
reported in CRIS at any time before index date (1st January 2013). We defined physical health 
multimorbidity as combination of two- or more physical health disease categories within one person 
at any given time before index date (Stubbs et al., 2016; Violan et al., 2014). These physical diseases 
were then grouped into the letter-based chapters from ICD-10 version 16 (World Health 
Organisation, 2016).   
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2.5 Semantic computing and learning system to capture physical health comorbidities 
on electronic patient records  
To identify patients’ physical health conditions from these clinical notes, we used SemEHR – an open 
source toolkit that integrates text mining and semantic computing for identifying mentions of UMLS 
(Unified Medical Language System) concepts from clinical documents (Wu et al., 2018). To identify 
mentions of a broad range of physical diseases (ICD-10; A00-N99), we mapped each top level ICD 
code (3-character code, e.g. A00) to a corresponding UMLS concept CUI (e.g. C0008354) using the 
mappings available at BioPortal (http://sparql.bioontology.org/) by querying its SPARQL Endpoint. 
The first benefit of using UMLS concepts instead of ICD-10 terms is that UMLS provides extensive 
synonyms for each concept, which helps identifying as many variants of disease mentions as 
possible. The second benefit comes from the comprehensive concept relations provided by UMLS, 
which helps the disambiguation in NLP and the identification of more disease subtypes.     
To optimise performance for identifying physical condition mentions, we used SemEHR’s continuous 
learning functionality to iteratively improve its text-mining model on these conditions. Briefly, each 
iteration includes sampling (random selection of a fixed number of mentions for each top-level 
condition), validation (manual assessment of samples on a specific browser-based user interface) 
and learning (validation results learnt by the system to improve the model). Based on previous 
studies on SLaM data, the recall (sensitivity) of SemEHR is generally very good (96-98%) for physical 
conditions at document level (Wu et al., 2018). The accuracy achieved for affirmed, recent and 
patient-suffered conditions was 83% ± 0.13(precision) - over 50 codes (2,960 instances) - at 
document level. The most comparable processing resource is CRIS-CODE (Jackson et al., 2017), which 
validated 46 mental health symptoms on CRIS with 85% precision. The SemEHR classification were 
found to have continued poor performance despite training for some physical disease systems, 
namely; bacterial infection (chapter A), neoplasm (chapter C), diseases of the blood and blood-
forming organs (chapter D), and eye and ear (chapter H). These were therefore not included in the 
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multimorbidity algorithm used for analyses described here, which instead ascertained viral infection 
(chapter B, e.g. HIV, mycoses, hepatitis.), endocrine (chapter E, e.g. diabetes mellitus, cystic fibrosis, 
obesity), neurologic (chapter G, e.g. Parkinson disease, epilepsy, Huntington disease), cardiovascular 
(chapter I, e.g. stroke, heart failure, myocardial infarction), respiratory (chapter J, e.g. asthma, 
bronchitis, chronic obstructive pulmonary disease), digestive (chapter K, e.g. liver diseases, gastric 
ulcer, irritable bowel syndrome), skin (chapter L, e.g. psoriasis, eczema, dermatitis), musculoskeletal 
(chapter M, e.g. systemic lupus, arthrosis, dorsopathies) and urogenital (chapter N, e.g. renal failure, 
endometriosis, diseases of genital (male/female) organs) systems. The precision at chapter level 
after removing poor-performing chapters is 86% ± 0.11. The source of validation data was generated 
in the study by two annotators (P.K. and R.S.) via 16 rounds of iterations. The precision at chapter-
level was estimated by manual assessments on sampled documents (80 documents per chapter of 
the last rounds). It needs to be noted that reported performances in this section are not for 
asserting conditions at patient-level, i.e. decide whether a patient had a physical condition or not. 
Instead, they were evaluated for the ability to identify whether a sequence of words is a 
contextualised condition mention (phenotype identification task). To translate phenotype task 
results to patient-level condition asserting, our previous study (Wu et al., 2018) on SLaM CRIS 
showed that a model with 85-87% precision at phenotype identification tasks on free-text can 
achieve 93-99% F-measure at patient-level for Hepatitis C and HIV diseases. The SemEHR has also 
been recently used and validated against other machine learning tools on Radiology Reports in 
Scotland (Gorinski et al., 2019).  
2.6 Outcomes and measures   
The index date for characterisation of the cohort and commencement of follow-up was defined as 1st 
January 2013, and the sample was thus restricted to all individuals who were alive at this time. The 
follow-up began on 1st January 2013 and ended on 31st December 2017, or at the day of death, 
whichever came first. The date of death of each deceased patient was obtained from CRIS, using a 
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linkage between SLaM’s EHR and the national mortality spine updated on at least a monthly basis 
and complete for the entirety of the follow-up period. 
2.7 Covariates  
We obtained sociodemographic data for the cohort in relation to the index date, including age (18-
39, 40-59, >60), sex (male, female), ethnicity (White, Black/Caribbean, others/mixed/unknown), and 
marital status (married/cohabiting, divorced, single), using structured EHR data accessed via CRIS. In 
the United Kingdom, mental health services have completed the Health of the Nation Outcome 
Scales (HONOS) among all patients. The HONOS is also widely used in Australia and New Zealand and 
is a validated measure with robust psychometric properties to routinely assess outcomes in mental 
health service users (Bebbington, Brugha, Hill, Marsden, & Window, 1999; Pirkis et al., 2005). We 
used five subscales from the routine HoNOS within the EHR, and these were obtained based on their 
specific relevance for this particular patient group, including agitated/aggressive behaviour, self-
injury, substance use, cognitive problems and depression scores. Each score was divided into three 
categories of not present (HoNOS subscale score 0), minimal or questionable (score 1) or significant 
(scores 2-4); these were based on the closest HoNOS recorded within a year prior to, or up to 3 
months after index date (1st January 2013).  
The address recorded as current or most recent at the index date was linked to the Index of Multiple 
Deprivation (IMD) score for that neighbourhood, derived from 2011 national Census data, and 
providing a measure of neighbourhood-level socioeconomic status (Department for Communities 
and Local Government, 2015).   
2.8 Statistical analysis 
Descriptive statistics for all variables were calculated as frequencies and percentages. The baseline 
characteristics included information on age (bands), sex, ethnicity, marital status, HoNOS, and 
deprivation score (divided in quantiles). In addition, the numbers of physical disease systems 
affected were grouped into categories from 0-6.  
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First, prevalence (percentage) of physical multimorbidity was calculated by combining two disease 
systems affected. The prevalence estimates of physical multimorbidity were demonstrated by 
ranking the most frequency occurring individual disease systems, and were expressed into 
categories of ≥10%, 5-9%, and <5%.  
Second, a Cox proportional hazards regression analysis was performed to study the relationship 
between physical multimorbidity and mortality for all possible disease combinations compared to 
those people with schizophrenia who had no recorded physical diseases. We adjusted for age at 
index and sex in the first adjusted model and then further adjusted for all other disease systems to 
account for an increased mortality driven by other disease systems than those combinations 
investigated. We calculated crude and adjusted HRs and their 95%CIs by using patients with SSD who 
had no recorded physical diseases as reference..  
Finally, the population attributable fraction (PAF) for mortality was calculated to assess the effect of 
different physical disease combinations on mortality. The PAF (expressed as a percentage) is a 
measure of proportion of deaths that might hypothetically be prevented if the disease combinations 
were not present. PAF calculations were carried out using STATA package “punafcc” for the adjusted 
cox regression model according to methods previously described (Spiegelman, Hertzmark, & Wand, 
2007). Statistically significance were defined as p <0.05. All analyses were conducted using STATA 
version 14. 
3. Results   
A total of 9775 people with SSD were assembled for the analysed cohort, with a mean (SD) age of 
45.9 (15.4) on the index date; 59.3% were males. Most of the sample were single (74.6%), and of 
black African/Caribbean (44.4%) or white (40.8%) ethnicity. The first column of Table 1 describes the 
characteristics of the total cohort.  
-Insert Table 1 here-  
12 of 26 
 
3.1 Prevalence of physical disease in patients with SSD 
Among the 9775 people with SSD, 1798 (18.4%) did not have any recorded physical disease systems 
affected, 1715 (17.5%) had one disease system affected, 1639 (16.8%) had two disease systems 
affected, and 1403 (14.4%) had three disease systems affected. The prevalence of people with 
physical multimorbidity was 6,262 (64.1%). The most common disease systems affected were 
neurological (49.7%), endocrine (42.4%), and respiratory (36.9%), see table 1. Figure 1 shows that 
the most frequently observed two-way disease combinations were neurologic-endocrine system 
(27.9%), followed by neurologic-respiratory system (25.2%) and neurologic-viral infection (24.9%).  
-Insert Figure 1 here-  
3.2 The association between baseline variables and mortality  
A total of 880 (9.0%) people with SSD died during the 5-year follow up period. As described in table 
1, in models including age and sex, the demographic variables that remained associated with 
increased mortality were increased age and male sex. Black compared to white ethnic group was 
associated with significant lower mortality. Of clinical characteristics, aggressive behaviour, self-
injury and substance abuse were all associated with increased mortality. Compared to people 
without physical disease, all specific physical disease systems had significantly increased mortality. 
People with SSD, who had two physical diseases or more, had increased mortality, compared to 
those without physical diseases. When comparing individuals with physical multimorbidity versus 
those with ≤2 physical disease systems, we observed a significant increased mortality in the 
multimorbidity group (HR: 1.23; 95% CI, 1.07-1.43).   
3.3 The association between physical health multimorbidity and mortality  
Table 2 displays Cox regression analyses of the associations between two-disease combinations and 
mortality. Among people with physical multimorbidity, most of the two-way combinations were 
associated with significantly increased mortality. Compared with the reference group, the highest 
age- and sex adjusted HR for mortality was 2.07 (95% CI, 1.42-3.02) for people with digestive-
urogenital diseases, 2.05 (95% CI, 1.45-2.88) for people with skin-urogenital diseases and 2.00 (95% 
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CI, 1.48-2.72) for people with respiratory-urogenital diseases. However, these specific combinations 
fell below statistical significance levels after further adjustment for other physical disease groups. 
In the final adjusted model, only respiratory diseases combined with other disease systems 
remained significantly increased, with the highest mortality observed in cardiovascular-respiratory 
diseases (HR: 2.23; 95% CI, 1.49-3.32), followed by respiratory-skin (HR: 2.06; 95% CI, 1.31-3.24) and 
respiratory-digestive (HR: 1.88; 95% CI, 1.14-3.11). Having respiratory disease alone compared to 
those without any physical disease did not significantly increase mortality, but only when respiratory 
diseases were combined with other disease systems, we observed an increased mortality. The only 
single physical disease system that alone increased mortality was cardiovascular disease (HR: 1.97; 
95% CI, 1.24-3.12), all others were insignificant, but the number of people who only had one disease 
systems affected were generally low.     
-Insert Table 2 here-  
3.4 Population attributable fractions of physical multimorbidity and mortality  
The top five highest PAFs are shown in table 3. The cardiovascular-respiratory disease combination 
had the highest PAF of 35.7%, followed by neurologic-respiratory (PAF: 32.7%) and respiratory-skin 
(PAF: 29.8%).  
-Insert Table 3 here-  
4. Discussion   
To the best of our knowledge, the current study is the first to investigate the association between 
physical multimorbidity and mortality in people with SSD. In this retrospective cohort study of 9,775 
patients with SSD with a mean age of 46 years, we found that 64% had physical health 
multimorbidity. The most frequently observed disease combinations were neurologic-endocrine 
system (28%), neurologic-respiratory system (25%), and viral infection-neurologic system (25%). 
Cardiovascular disease combined with respiratory disease had highest mortality rate (HR: 2.23; 95% 
CI, 1.49-3.32) and at the same time showed highest PAF (35.7%), but also respiratory-neurologic (HR: 
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1.84; 95% CI, 1.35-2.52, PAF: 32.7%) and respiratory-skin (HR: 2.06; 95% CI, 1.31-3.24, PAF: 29.8%) 
were associated with excess mortality in people with SSD, compared to those without physical 
diseases.     
Previous studies have reported increased risk of physical health multimorbidity in people with 
schizophrenia (Gabilondo et al., 2017; Stubbs et al., 2016). Our study is the first to include a large 
scale of physical diseases to explore the most frequently co-occurring physical disease systems in 
people with SSD. Previous findings have reported prevalence of physical multimorbidity of 29% 
(Gabilondo et al., 2017), 33% (Smith et al., 2013), 36% (Stubbs et al., 2016) and 39% (Correll, Ng-
Mak, et al., 2017), in people with schizophrenia. Our prevalence rate of 64% with physical 
multimorbidity is higher than the prevalence rates observed in those studies, but given the 
differences in the inclusion criteria of physical diseases, it is not surprising that we found higher 
prevalence rates than those who only included specific physical diseases. The most common physical 
disease systems affected were neurologic, endocrine, and respiratory systems, although we cannot 
determine whether they are higher than expected due to the lack of a non-schizophrenia 
comparison group. However, neurologic diseases, especially epilepsy and migraine, have been 
previously linked to psychosis (Clancy, Clarke, Connor, Cannon, & Cotter, 2014). It has also previously 
been suggested that there might be similar genetic pathways between schizophrenia and neurologic 
conditions (Ferentinos & Dikeos, 2012). On the other hand, the increased prevalence of neurologic 
diseases observed in this population may also be explained by the side effects of first-generation 
antipsychotics, as many patients will experience extrapyramidal side effects (Miller et al., 2008). 
Endocrine diseases, including diabetes mellitus, obesity, and thyroid diseases are increased in 
patients with schizophrenia compared to the general population (Pillinger, Beck, Stubbs, & Howes, 
2017; M. C. M. Ryan, Collins, & Thakore, 2003). This can partly be explained by unhealthy lifestyle 
risk behaviors (Vancampfort, Firth, et al., 2017), side effects from second-generation antipsychotics 
(Manu et al., 2015), as well as common genetic pathways between psychosis and metabolic 
disorders (Tandon, Keshavan, & Nasrallah, 2008). Most studies regarding physical multimorbidity in 
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the general population have focused on populations above the age of 60 years (Guisado-Clavero et 
al., 2018; Schäfer et al., 2010), making comparison between people with SSD and the general 
population much more challenging. However, high smoking rates, substance abuse, unhealthy 
dietary behaviours (Firth et al., 2018) as well as less physical activity (Stubbs, Vancampfort, et al., 
2018) are important risk factors for physical multimorbidity in people with psychosis (Laursen et al., 
2013; Ringen, Engh, Birkenaes, Dieset, & Andreassen, 2014; Vancampfort, Koyanagi, et al., 2017), 
and might also explain the increased prevalence of respiratory diseases. Future studies are needed 
to explore the main contributing factors that predict development of co-occurring physical diseases, 
as well as the effectiveness of early screening and intervention to reduce the likelihood of 
developing physical multimorbidity in people with SSD.  
Our data clearly demonstrate that physical health multimorbidty is an important contributor to the 
excess mortality in people with SSD. Previous research in people with physical multimorbidity from 
the general population has demonstrated that the number of physical comorbidities are associated 
with increased mortality (Ferrer, Formiga, Sanz, Almeda, & Padrós, 2017). No other studies have 
investigated the PAF of physical diseases for mortality in people with schizophrenia, so comparisons 
are difficult, since previous studies have only focused on single comorbid diseases. In the current 
study, we showed that a single disease was not associated with an increased mortality (however it 
reached almost significance), but patients who had two or more physical diseases were associated 
with increased mortality. The risk of premature mortality in patients suffering from two-way disease 
combinations was further increased compared to those with none or single physical disease 
condition. This could indicate that the excess mortality observed in people with SSD is not driven by 
the presence of a single disease system but is associated with the presence of physical 
multimorbidity. The finding that respiratory, cardiovascular and neurologic disease combinations 
had the highest impact on mortality adds impetus to further study the underlying aetiology of the 
impact of these disease combinations on the excess mortality in people with SSD. Patients with 
physical multimorbidity may find that one physical disorder creates difficulty in the management of 
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another, which could affect compliance with medical treatment for their health condition, and 
thereby possibly explain some of the increased mortality. Smoking is an important confounder that 
affects multiple organ systems, but especially cardiovascular and respiratory systems (Yanbaeva, 
Dentener, Creutzberg, Wesseling, & Wouters, 2007), and we cannot quantify the possible effect of 
this or other confounders on the excess mortality observed. Whether these disease systems affected 
are the same relative increase in mortality in patients with SSD as compared to the general 
population remain unanswered, as we did not have any data on a psychiatric healthy population. 
However, more research is required to unravel the findings of the current study, which should be 
given high priority because of this excess mortality.   
4.1 Limitations  
Whilst our data provide novel insights into this neglected area, some limitations need to be 
addressed. First, we were only able to follow patients for 5 years, and there are potentially large 
differences in short-term and long-term outcome for different physical disease systems. Second, we 
did not have information regarding the specific time-point of the recorded physical disease, as some 
might have had the diagnosis for several years, while others might just have received the diagnosis, 
which may have led to differences in the estimated mortality rates. Third, we did not assess the 
severity of the physical condition, and we are aware that within each disease system investigated 
there are large variations between physical conditions in terms of importance for mortality. Fourth, 
we had incomplete disorder systems captured by the SemEHR, since we did not develop sufficient 
accuracy for cancer (mainly due to feared entity) as well as bacterial infections (because some 
vaccinations were captured here). Fifth, the NLP and its performance needs to be further developed 
in terms of accuracy, but any inaccuracy would reduce rather than exaggerate associations with 
mortality. Nevertheless, our findings are showing good predictive validity and a novel multimorbidity 
measure that could be routinely applied to EHRs for health monitoring and risk stratification. Sixth, 
there is an issue as to whether physical health conditions are recorded at all in a mental health 
record, and it might even be possible that physical conditions are more likely to be recorded in 
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people with more severe mental disorders or risk states, but we were unable to adjust for this in the 
current data. On the other hand, when a physical health disorder is recorded, it means that it is 
recognized, so there could also be an obscuring effect of recognition and relatively better outcomes. 
The increased risk of suicide mortality in these patients challenges the findings observed in the 
current study, as many patients die early without having the chance to develop somatic diseases 
(competing risk). This is often considered as a major limitation is observations studies. It is also a 
major limitation that the current data did not include information on important confounders, such 
as smoking and alcohol consumption as well as levels of physical activity and intake of healthy diet, 
which are important variables in morbidity and mortality outcomes. For example, the finding that 
respiratory system is a strong contributor for morbidity and mortality in patients with SSD could be 
confounded by the excessive rates of smokers in patients with SSD, and we would have expected to 
reduce some of the respiratory mortality if we were able to include smoking as a variable in our 
regression model. On the other hand, smoking cessation is very difficult to implement in patients 
with SSD, and some patients even use smoking as self-medication to handle negative and cognitive 
symptoms (Winterer, 2010), which again challenges the use of such adjustment in our analysis.  
Lastly, when considering the generalisability of the cohort, we included people with SSD known to 
mental healthcare, so it is not possible to generalize these findings to those people with 
undiagnosed disorders or those treated in primary care alone, which might include people with 
better prognosis of mental disorders.  
5. Conclusion    
In a large representative sample, we identified that approximately two thirds of people with 
schizophrenia had physical multimorbdity. The current data is the first to address physical 
multimorbidity and its association to mortality in people with SSD, and suggest that cardiovascular-
respiratory, neurologic-respiratory, and respiratory-skin disease combinations had the highest 
impact on mortality rates. Our data indicate that current treatment models for improving physical 
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health and reducing premature mortality in SSD need to acquire a more coordinated approach and 
move beyond the consideration of single disease systems.   
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Table 1. Baseline characteristics and their association to death in people with SSD.  
 Schizophrenia Spectrum Disorders, N=9775 
Variables n (%)   Adjusted HR (95% CI)* 
Age, n (%)   
 18-39 3707 (37.9)  Reference 
 40-59 4377 (44.8)  2.59 (2.06-3.25) 
 ≥60 1691 (17.3)  13.37 (10.73-16.65)  
Gender, n (%)     
 Females  3983 (40.7)  Reference 
 Males  5792 (59.3)  1.37 (1.20-1.58)  
Marital status, n (%)     
 Married/cohabiting 1096 (11.2)  Reference 
 Divorced/widowed   1267 (13.0)  1.14 (0.90-1.44)  
 Single 7293 (74.6)  1.14 (0.92-1.41)  
 Unknown 119 (1.2)  0.69 (0.28-1.69)  
Ethnicity, n (%)     
 White 3990 (40.8)  Reference 
 Black African/Caribbean  4339 (44.4)  0.73 (0.63-0.85) 
 Other/unknown  1445 (14.8)  0.84 (0.68-1.04)  
Social deprivation index (quintiles), n (%)    
 1 (Least deprived)  1957 (20.0)  Reference 
 2 1953 (20.0)  0.90 (0.73-1.11) 
 3 1979 (20.3)  0.91 (0.74-1.13) 
 4 1939 (19.8)  1.06 (0.86-1.30) 
 5 (Most deprived)  1947 (19.9)  1.06 (0.86-1.30) 
HoNOS domain score    
Agitated/aggressive behaviour, n (%)     
 0 7356 (75.2) Reference 
 1 1327 (13.6)  1.02 (0.81-1.28)  
 2-4 1073 (11.0)  1.29 (1.02-1.62)  
 Missing 19 (0.2)  
Self-injury, n (%)      
 0 9145 (93.6) Reference 
 1 373 (3.8) 1.21 (0.82-1.78)  
 2-4 236 (2.4)  1.60 (1.02-2.49)  
 Missing 21 (0.2)  
Substance abuse, n (%)      
 0 8012 (82.0)  Reference 
 1 634 (6.5) 1.18 (0.86-1.62)  
 2-4 1078 (11.0) 1.56 (1.22-1.98)  
 Missing 51 (0.5)  
Cognitive problems, n (%)      
 0 7151 (73.2)  Reference 
 1 1488 (15.2)  1.10 (0.90-1.34)  
 2-4 1115 (11.4)  1.09 (0.87-1.35)  
 Missing 21 (0.2)  
Depression, n (%)     
 0 6434 (65.8) Reference 
 1 1980 (20.3)  1.16 (0.96-1.40)  
 2-4 1333 (13.6)  1.09 (0.86-1.38)   
 Missing 28 (0.3)  
Number of physical disease systems affected, n (%)     
 0 1798 (18.4) Reference 
 1 1715 (17.5)  1.26 (0.99-1.62)  
 2 1639 (16.8) 1.30 (1.02-1.66) 
 3 1403 (14.4) 1.34 (1.04-1.72) 
 4 1185 (12.1) 1.41 (1.09-1.83)  
 5  846 (8.7) 1.62 (1.23-2.13)  
 6+ 1189 (12.2) 1.43 (1.11-1.85)  
Disease systems affected, n (%)      
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 No disorder  1798 (18.4) Reference 
 Viral infection   3758 (38.5) 1.38 (1.11-1.71) 
 Endocrine  4141 (42.4)  1.30 (1.06-1.61)  
 Neurologic   4859 (49.7)  1.33 (1.08-1.64)  
 Cardiovascular 2621 (26.8)  1.47 (1.19-1.83)  
 Respiratory  3609 (36.9)  1.70 (1.38-2.10) 
 Digestive  1822 (18.6)  1.53 (1.22-1.93)  
 Skin  2144 (21.9) 1.44 (1.15-1.80)  
 Musculoskeletal  2447 (25.0) 1.27 (1.01-1.59) 
 Urogenital  711 (7.3)  1.77 (1.35-2.32) 
*Adjusted for age and gender  
 
Figure 1. Prevalence rates of two-way disease system combinations presented as percentages. 
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Table 2. Cox proportional hazards regression of physical disease combinations and their association to 
death.   
* Adjusted for age and gender  
† Adjusted for age, gender, and all other physical disease systems (chapter B-N)  
Physical disease combinations  Crude HR (95% CI) Adjusted HR (95% CI)* Adjusted  HR (95% CI)† p 
No physical disease 1.0 (Ref.) 1.0 (Ref.) 1.0 (Ref.)   
Viral infection only 1.11 (0.67-1.82) 1.31 (0.80-2.17) N/A ns  
Viral infection + Endocrine  1.39 (1.10-1.76) 1.33 (1.05-1.69) 1.19 (0.79-1.77) ns  
Viral infection + Neurologic 1.37 (1.08-1.72) 1.34 (1.06-1.69) 0.92 (0.62-1.37) ns  
Viral infection + Cardiovascular  1.75 (1.37-2.23) 1.44 (1.13-1.84) 1.06 (0.64-1.77) ns  
Viral infection + Respiratory  1.74 (1.38-2.18) 1.64 (1.31-2.06) 1.65 (1.17-2.33)  <0.01 
Viral infection + Digestive 1.84 (1.42-2.38) 1.59 (1.23-2.07) 1.08 (0.61-1.90)  ns  
Viral infection + Skin 1.57 (1.22-2.03) 1.35 (1.04-1.74)  0.96 (0.57-1.63)  ns  
Viral infection + Musculoskeletal  1.55 (1.20-1.99)  1.39 (1.08-1.79)  1.06 (0.64-1.77) ns  
Viral infection + Urogenital  2.00 (1.42-2.80)  1.65 (1.18-2.32) 0.75 (0.26-2.18) ns  
     
Endocrine only  1.50 (1.01-2.22) 1.23 (0.83-1.82) N/A ns  
Endocrine + Neurologic 1.34 (1.07-1.69) 1.23 (0.98-1.54) 0.80 (0.56-1.14) ns  
Endocrine + Cardiovascular 1.69 (1.33-2.15) 1.29 (1.01-1.64)  0.83 (0.52-1.30)  ns  
Endocrine + Respiratory 1.72 (1.37-2.16) 1.62 (1.29-2.04) 1.72 (1.18-2.49)   <0.01 
Endocrine + Digestive 1.58 (1.21-2.07) 1.42 (1.09-1.86) 1.11 (0.63-1.94) ns  
Endocrine + Skin 1.63 (1.26-2.09) 1.41 (1.09-1.82) 1.51 (0.95-2.42) ns  
Endocrine + Musculoskeletal 1.39 (1.08-1.79) 1.21 (0.93-1.56) 0.94 (0.59-1.50)  ns  
Endocrine + Urogenital 2.09 (1.53-2.86) 1.66 (1.22-2.28) 0.80 (0.36-1.75) ns  
     
Neurologic only  1.09 (0.73-1.63) 1.20 (0.80-1.79) N/A ns  
Neurologic + Cardiovascular 1.85 (1.47-2.33) 1.46 (1.16-1.83) 1.22 (0.84-1.77) ns  
Neurologic + Respiratory 1.86 (1.49-2.32) 1.71 (1.38-2.14) 1.84 (1.35-2.52)  <0.001 
Neurologic + Digestive 1.78 (1.39-2.28) 1.58 (1.24-2.03) 1.19 (0.76-1.87) ns  
Neurologic + Skin 1.73 (1.36-2.20) 1.46 (1.15-1.86) 1.31 (0.83-2.05) ns  
Neurologic + Musculoskeletal 1.45 (1.14-1.86) 1.29 (1.01-1.66) 0.67 (0.41-1.10) ns  
Neurologic + Urogenital 2.25 (1.68-3.03) 1.83 (1.36-2.46) 1.08 (0.52-2.31) ns  
     
Cardiovascular only  3.04 (1.92-4.81) 1.97 (1.24-3.12) N/A  
Cardiovascular + Respiratory 2.34 (1.86-2.95) 1.78 (1.41-2.25) 2.23 (1.49-3.32)  <0.001 
Cardiovascular + Digestive 1.93 (1.47-2.54) 1.51 (1.15-2.00) 1.33 (0.65-2.71) ns  
Cardiovascular + Skin 2.00 (1.54-2.60) 1.46 (1.13-1.90) 1.07 (0.57-2.00) ns  
Cardiovascular + Musculoskeletal 1.72 (1.32-2.25) 1.30 (0.99-1.69) 0.71 (0.37-1.37) ns  
Cardiovascular + Urogenital 2.64 (1.92-3.65) 1.81 (1.31-2.50) 0.71 (0.26-1.93) ns  
     
Respiratory only  1.16 (0.67-2.03) 1.12 (0.64-1.95) N/A ns  
Respiratory + Digestive 2.23 (1.74-2.86) 1.88 (1.47-2.41) 1.88 (1.14-3.11)  <0.05  
Respiratory + Skin 2.04 (1.60-2.60) 1.75 (1.37-2.24) 2.06 (1.31-3.24)  <0.01  
Respiratory + Musculoskeletal 1.88 (1.47-2.40) 1.62 (1.27-2.07) 1.57 (1.01-2.44)  <0.05 
Respiratory + Urogenital 2.73 (2.02-3.70) 2.00 (1.48-2.72) 1.39 (0.65-2.96) ns  
     
Digestive only  1.34 (0.59-3.06) 1.13 (0.49-2.58) N/A ns  
Digestive + Skin  1.92 (1.45-2.55) 1.59 (1.20-2.12) 0.96 (0.44-2.08) ns  
Digestive + Musculoskeletal 1.80 (1.36-2.38) 1.54 (1.16-2.04) 0.71 (0.33-1.54) ns  
Digestive + Urogenital  2.65 (1.82-3.86) 2.07 (1.42-3.02) 1.97 (0.63-6.15) ns  
     
Skin only  1.35 (0.66-2.77) 1.03 (0.50-2.12) N/A ns  
Skin + Musculoskeletal 1.75 (1.33-2.29) 1.41 (1.07-1.85) 0.68 (0.35-1.31) ns  
Skin + Urogenital 2.70 (1.92-3.79) 2.05 (1.45-2.88) 1.39 (0.45-4.28) ns  
     
Musculoskeletal only  0.9 (0.42-1.94) 0.88 (0.41-1.88) N/A ns  
Musculoskeletal + Urogenital   2.42 (1.71-3.41) 1.85 (1.31-2.61) 0.70 (0.25-1.97)  ns  
     
Urogenital only  3.68 (1.50-9.02) 1.87 (0.76-4.61) N/A ns  
26 of 26 
 
N/A, not applicable   
Significance testing for the final adjusted model only (†) 
 
Table 3. Top five highest population attributable fractions (PAFs) for 5-year mortality associated with 
physical multimorbidity combinations as well as single diseases in patients with SSD 
PAF calculated by an adjusted cox regression analysis adjusted for age, gender, and all other physical disease systems.  
Abbreviations: PAF, population attributable fraction  
Physical disease combinations and single diseases ranked by PAF PAF estimate (%, 95%CI) p 
No physical disease Ref.  Ref. 
   
Physical multimorbidity    
Cardiovascular + Respiratory  35.7 (23.0-46.3) <0.001 
Neurologic + Respiratory 32.7 (19.3-43.8)  <0.001 
Respiratory + Skin 29.8 (15.8-41.5)  <0.001 
Endocrine + Respiratory 27.5 (11.7-40.5)  <0.001 
Respiratory + Digestive 26.4 (9.4-40.3) <0.001 
   
Single diseases    
Cardiovascular alone  8.1 (4.2-9.6) <0.001 
Neurologic alone  3.6 (-3.9-10.6) ns  
Endocrine alone 4.2 (-3.2-11.1) ns 
Respiratory alone 1.2 (-4.6-6.6)  ns 
Skin alone 0.2 (-4.5-4.8) ns 
Digestive alone 0.6 (-3.3-4.3)  ns 
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Reviewer #1 
 
Well written overall. Minor grammar corrections. However, the substantial amount of work that has gone on in writing 
the article has given results (and the message) the magnitude of which can be accommodated into a brief report. 
Authors may consider this.  
 
Response 
Thank you for your positive feedback and also the suggestion to improve the grammar within our manuscript. The 
manuscript will be corrected by our proofreader from our research department before resubmitting. We appreciate the 
suggestion to consider the study as a brief report, however, we still believe that this study fulfills the requirement for an 
“original investigation”. However, if the editor decides this manuscript to be a brief report, we would of course accept 
this decision, and make the necessary changes.    
Reviewer #2 
The authors have used a population based study to study the effects of somatic co-morbidity/multi-morbidity in 
addition to Schizophrenia. Time to death and 5-year mortality are the main outcomes of investigation. Though the 
research motive is clear and very relevant for reducing morbidity and mortality outcomes, this investigation is not 
enough advance or of enough impact for the journal. My biggest critique is that no smoking data or alcohol usage is 
used as predictors in the model. The authors should at least acknowledge this in their limitations as they are strong 
confounds especially in the said population. The results table in a way allude to this limitation, with respiratory system 
being a strong contributor for morbidity outcomes. 
 
Response 
Thank you for this very valid comment. We highly appreciate your concern regarding lack of information on smoking 
and alcohol, which we agree are important variables for mortality, especially in this specific study population. 
However, we were not able to include such variables in our data extraction. We agree that this should be discussed in 
the limitation section of the paper, which we apologize for not having included in the initial draft, thus we have now 
corrected the limitation section to include a more comprehensive discussion of the contribution of these confounders to 
our study findings.  
Revision: Added to the limitation section  
“It is a major limitation that the current data did not include information on important confounders, such as smoking 
and alcohol consumption as well as levels of physical activity and intake of healthy diet, which are important variables 
in morbidity and mortality outcomes. For example, the finding that respiratory system is a strong contributor for 
morbidity and mortality in patients with SSD could be confounded by the excessive rates of smokers in patients with 
SSD, and we would have expected to reduce some of the respiratory mortality if we were able to include smoking as a 
variable in our regression model. On the other hand, smoking cessation is very difficult to implement in patients with 
*Response to Reviewers
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SSD, and some patients even use smoking as self-medication to handle negative and cognitive symptoms (REF), which 
again challenges the use of such adjustment in our analysis.”  
Reviewer #3 
This manuscript provides a population approach to understanding the association between physical multi morbidity and 
mortality in schizophrenia spectrum disorders. The study method uses computer programs to record physical morbidity 
from a large database. Results are in keeping with current understanding and the novelty of findings is rather limited. 
Important confounding elements are not strictly covered for, partly due to the limited inherent properties of the data 
collecting process. Here are my specific comments: 
Response  
We are pleased that reviewer #3 acknowledges the importance of our work and offers additional input to help improve 
our manuscript. We are unaware of any previous representative cohort studies that have specifically investigated 
physical multimorbidity patters and mortality in schizophrenia and believe the paper fills an important gap in the 
literature. In fact, this is a gap, which we have identified in our forthcoming (released July 22nd) Lancet Commission to 
improve the physical health of people with mental disorders.   
Reviewer #3 #1 
Introduction: The clinical relevance of this area needs to be supplemented with the novelty that this particular 
investigation adds to the available literature. The authors state "little is known about the prevalence and impact of 
physical health multimorbidity"; however, they also quote a range of studies indicating "a higher risk of physical health 
multimorbidity (in schizophrenia) compared to the general population". The specifics of the "improved evidence base" 
this article can provide is also wanting. 
Response: 
Thank you very much for highlighting this inconsistency in our introduction as well as the lack of description regarding 
the novelty of our study. We agree that some of the sentences should be revised in our introduction, and therefore the 
following revisions have been made in the manuscript:  
Revision: 
Before: “Whilst there have been concerted efforts to understand poor physical health in schizophrenia, little is known 
about the prevalence and impact of physical health multimorbidity.” 
Now: “Whilst there have been concerted efforts to understand poor physical health in schizophrenia, little is known 
about the impact of physical health multimorbidity on mortality in these patients.” 
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The following has been added in the introduction:   
 “The study by Gabilondo et al. (2017) showed that physical disease clusters of neuropsychiatric conditions 
(Parkinson, dyspepsia, cerebrovascular disease) as well as cardiovascular and respiratory disease clusters were most 
common. Stubbs et al. (2016) reported that psychosis patients had high levels of asthma combined with diabetes, 
angina pectoris or tuberculosis, and arthritis combined with angina pectoris, and hearing problems combined with 
visual impairment or edentulism. Even though such combinations show that physical morbidities co-occur frequently in 
patients with SSD, no studies have to date investigated the impact of such combinations to mortality, which is 
necessary in order to understand and possibly reduce the premature mortality in patients with SSD.”  
Reviewer #3 #2 
Method: Identification of physical multi morbidity is solely dependent on the accuracy of the computer program used 
to parse through clinical notes. This is a major advancement, yet a limitation - as it is not a gold standard method of 
ascertaining morbidity. Hence, this needs to be highlighted in the title and abstract of the manuscript. If these programs 
have been used in any manuscripts other than Wu et al., 2018 - those may be quoted. When the authors say "The 
precision at chapter level after removing poor-performing chapters is 86% ± 0.11. " - what is the source of data and 
confirmation method for estimating precision? Also, can you provide examples of physical disorders coded under each 
system - neurological, endocrine, respiratory, skin, etc.? 
Response:  
Thank you again for your suggestion. We agree that the title and abstract should reflect the methodology used in our 
study, thus the following revision has been made in the title:   
Before: “Physical health multimorbidity and its association to mortality rates in people with schizophrenia spectrum 
disorders: a retrospective cohort study” 
Now: “Association of physical health multimorbidity with mortality in people with schizophrenia spectrum disorders: 
Using a novel semantic search system that captures physical diseases in electronic patient records” 
The following correction has been made in the abstract:  
Before: “A retrospective cohort study between 2013 and 2017. All people with a diagnosis of SSD (ICD-10: F20-F29), 
who had contact with secondary mental healthcare within South London during 2011-2012 were included. Physical 
health conditions were ascertained from electronic mental health records and all-cause mortality from a national 
registry. Hazard ratios (HRs) and population attributable fractions (PAFs) were calculated for associations between 
physical multimorbidity and all-cause mortality.” 
Now: “A retrospective cohort study between 2013 and 2017. All people with a diagnosis of SSD (ICD-10: F20-F29), 
who had contact with secondary mental healthcare within South London during 2011-2012 were included. We used a 
novel semantic search system to capture physical health conditions from electronic mental health records, and all-
cause mortality were retrieved from a national registry. Hazard ratios (HRs) and population attributable fractions 
(PAFs) were calculated for associations between physical multimorbidity and all-cause mortality.” 
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The computer program (SemEHR) has been recently used and validated against other machine learning tools on 
Radiology Reports in Scotland. It is described in the following reference (quoted in the manuscript). 
“Gorinski, Philip John, Honghan Wu, Claire Grover, Richard Tobin, Conn Talbot, Heather Whalley, Cathie Sudlow, 
William Whiteley, and Beatrice Alex. "Named Entity Recognition for Electronic Health Records: A Comparison of 
Rule-based and Machine Learning Approaches." Accepted by the second UK healthcare text analytics conference – 
HealTAC 2019; arXiv preprint arXiv:1903.03985 (2019).” 
Revision: p. 9 (additional lines added) 
“The SemEHR has been recently used and validated against other machine learning tools on Radiology Reports in 
Scotland (Gorinski et al., 2019).”  
Regarding the precision of poor performing chapters (what is the source of data and confirmation method for 
estimating precision?). The source of (validation) data was generated in the study by two annotators (P.K. and R.S.) via 
16 rounds of iterations. The precision at chapter-level was estimated by manual assessments on sampled documents (80 
documents per chapter of the last rounds). 
Revision: p. 9  
Before: “The precision at chapter level after removing poor-performing chapters is 86% ± 0.11.”  
Now: “The precision at chapter level after removing poor-performing chapters is 86% ± 0.11. The source of 
(validation) data was generated in the study by two annotators (P.K. and R.S.) via 16 rounds of iterations. The 
precision at chapter-level was estimated by manual assessments on sampled documents (80 documents per chapter of 
the last rounds).”  
The suggestion to include specific physical disease examples within each physical main category is much appreciated, 
and we have now corrected the description of these categories in the methods by including few examples (the most 
common) within each category:  
Before: “These were therefore not included in the multimorbidity algorithm used for analyses described here, which 
instead ascertained viral infection (chapter B), endocrine (chapter E), neurologic (chapter G), cardiovascular (chapter 
I), respiratory (chapter J), digestive (chapter K), skin (chapter L), musculoskeletal (chapter M) and urogenital 
(chapter N) systems.” 
Now: “These were therefore not included in the multimorbidity algorithm used for analyses described here, which 
instead ascertained viral infection (chapter B, e.g. HIV, mycoses, hepatitis.), endocrine (chapter E, e.g. diabetes 
mellitus, cystic fibrosis, obesity), neurologic (chapter G, e.g. Parkinson disease, epilepsy, Huntington disease), 
cardiovascular (chapter I, e.g. stroke, heart failure, myocardial infarction), respiratory (chapter J, e.g. asthma, 
bronchitis, chronic obstructive pulmonary disease), digestive (chapter K, e.g. liver diseases, gastric ulcer, irritable 
bowel syndrome), skin (chapter L, e.g. psoriasis, eczema, dermatitis), musculoskeletal (chapter M, e.g. systemic lupus,  
 
 
 
 
 
 
 
 
 
5 
 
 Aalborg University Hospital, Psychiatry,  Mølleparkvej 10,   9100 Aalborg   
Unit for Psychiatric 
Research 
Mølleparkvej 10 
9000 Aalborg 
 
Phd Student 
Pirathiv Kugathasan 
Direct +45 28597494 
divkugathasan@gmail.com 
 
22 June 2019 
 
 
 
 
 
 
arthrosis, dorsopathies) and urogenital (chapter N, e.g. renal failure, endometriosis, diseases of genital (male/female) 
organs) systems.” 
Reviewer #3 #3 
Outcomes: Was there any information on causes of mortality that could have been available from the databased 
accessed by the investigators? Was suicide as a cause for mortality excluded? Similarly, what steps were taken to 
ensure that the mortality was not related to the physical multi morbidity to prevent inferences of false / confounding 
associations?  
Response: 
Thank you for this comment. It is not possible to extract causes of death from the clinical database (CRIS) used, as we 
were only able to access status and time of death. This type of information would only have been possible to retrieve 
from the Office of National Statistics (ONS), which we unfortunately did not have access to. Therefore, our sample 
included all deaths (also suicide and other unnatural deaths), which of course challenges the interpretation of our 
findings. However, we agree that suicide contribute to the excess mortality in patients with schizophrenia spectrum 
disorders, perhaps even conflicting the outcomes observed in the group of people with zero somatic diseases, as our 
results showed no significant differences between one and zero somatic diseases. We believe that the high risk of 
suicide mortality in people with SSD conflicts the current study design due to the problem regarding the competing risk 
phenomenon, as a majority of these patients might die early preventing people from developing somatic disease. We 
appreciate this concern, and we have added some sentences in the limitation section to elucidate this problem.   
Revision: p. 17. Added to the limitation section  
“The increased risk of suicide mortality in these patients challenges the findings observed in the current study, as many 
patients die early without having the chance to develop somatic diseases (competing risk). This is often considered as a 
major limitation is observations studies.”  
Reviewer #3 #4 
Covariates: The authors use data from the Health of the Nation Outcome Scales (HoNOS). Please provide details of 
how (structured interview, clinical consult notes, etc) this information is recorded and who (trained raters, experts, 
GPS) rates these and how often? Also, substance abuse is an important confounder here. What steps were taken to gain 
adequate information about nicotine, alcohol, cannabis and other SUDs? 
Response 
Thank you very much for this comment. In the United Kingdom, since the mid 1990’s mental health services have 
completed the HONOS scale among all patients. The HONOS is also widely used in Australia and New Zealand and is 
a validated measure with robust psychometric properties to routinely assess outcomes in mental health service users.  
The HONOS scale has 12 items and it has been used in over 40 papers published from the CRIS database and 290 on 
Pubmed as of 21/6/2019.   
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https://www.ncbi.nlm.nih.gov/pubmed/?term=Health+of+the+Nation+Outcome+Scales 
All mental healthcare staff receive training in completing the HONOS and this is completed by care coordinators. 
Regarding your questions on smoking and SUDs. This information is not available for all patients and we have updated 
our limitations to state this (please see response to comment #2.   
Reviewer #3 #5 
Analysis: Why was physical multmorbidity categorised?  
"We calculated crude and adjusted HRs and their 95%CIs by using patients with schizophrenia who had no recorded 
physical diseases as reference." - was this from the same dataset? Why was this restricted to schizophrenia and not 
schizophrenia spectrum disorders? 
 
Response 
We categorized physical multimorbidity due to the high level of patients with SSD who had 2 or more physical 
diseases (64.1%). When analyzing the data, it is important to level out or show the differences in cases within the 
specific number of diseases. If we observed the largest effect of mortality in the highest number of physical diseases, it 
would have been more useful to look into more disease combinations than the two disease combination that we chose 
to calculate. But again the results reported in table 1 showed that there was no significant difference in mortality rates 
from two physical diseases to six physical diseases, but a general significant effect of increased physical 
multimorbidity on mortality when compared to the reference group (zero physical disease).  
Regarding the second concern of the statement highlighted, we apologize the written mistake that regrettably created 
this confusion. All analysis is based on the same data and therefore it should correctly have been “patients with 
schizophrenia spectrum disorders” and not just “schizophrenia”. We have corrected this in our manuscript:  
Revision:      
“We calculated crude and adjusted HRs and their 95%CIs by using patients with SSD who had no recorded physical 
diseases as reference.” 
 
Sincerely,  
 
Pirathiv Kugathasan and Brendon Stubbs on behalf of co-authors  
 
Role of the funding source  
Brendon Stubbs is supported by a Clinical Lectureship (ICA-CL-2017-03-001) jointly funded by Health 
Education England (HEE) and the National Institute for Health Research (NIHR). Brendon Stubbs is part 
funded by the NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust. 
Brendon Stubbs is also supported by the Maudsley Charity, King’s College London and the NIHR South 
London Collaboration for Leadership in Applied Health Research and Care (CLAHRC) funding. This paper 
presents independent research. The views expressed in this publication are those of the authors and not 
necessarily those of the acknowledged institutions. 
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